Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (−) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.
1. A method of treating an arthritic condition, which comprises administering to a patient having an arthritic condition a therapeutically effective amount of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione.
2. The method of claim 1 , wherein the arthritic condition is rheumatoid spondylitis.
3. The method of claim 1 , wherein the compound is administered orally.
4. The method of claim 3 , wherein about 5 mg to about 500 mg of the compound is administered per day.
5. The method of claim 3 , wherein about 10 mg to about 200 mg of the compound is administered per day.
6. The method of claim 3 , wherein about 10 mg to about 100 mg of the compound is administered per day.
7. The method of claim 3 , wherein the compound is administered twice daily in equally divided doses.
8. The method of claim 3 , wherein the stereomerically pure compound comprises greater than about 90% by weight of (+) isomer based on the total weight percent of the compound.
9. The method of claim 3 , wherein the stereomerically pure compound comprises greater than about 95% by weight of (+) isomer based on the total weight percent of the compound.
10. The method of claim 3 , wherein the stereomerically pure compound comprises greater than about 97% by weight of (+) isomer based on the total weight percent of the compound.
11. The method of claim 3 , wherein the compound is administered in capsule form.
12. The method of claim 1 , wherein the capsule contains about 10 mg of the compound.
13. The method of claim 11 , wherein the capsule contains about 20 mg of the compound.
14. The method of claim 11 , wherein the capsule contains about 25 mg of the compound.
15. The method of claim 11 , wherein the capsule contains about 50 mg of the compound.
16. The method of claim 1 , wherein the compound is administered in tablet form.
17. The method of claim 16 , wherein the tablet contains about 10 mg of the compound.
18. The method of claim 16 , wherein the tablet contains about 20 mg of the compound.
19. The method of claim 16 , wherein the tablet contains about 25 mg of the compound.
20. The method of claim 16 , wherein the tablet contains about 50 mg of the compound.
21. A method of treating an arthritic condition, which comprises orally administering to a patient having an arthritic condition about 10 mg to about 100 mg of a compound which is stereomerically pure (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione comprising greater than about 97% by weight of (+) isomer wherein the compound is administered in the form of a tablet or capsule twice daily in equally divided doses.
22. The method of claim 21 , wherein the arthritic condition is rheumatoid spondylitis.